Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180167
Status:
COMPLETED
Last Update Posted:
2010-08-20
First Post:
2005-09-13
Brief Title:
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 DA Versus Mitoxantrone With Intermittent AraC
Sponsor:
Technische Universität Dresden
Organization:
Technische Universität Dresden
Study Overview
Official Title:
Therapy of AML in Patients Older Than 60 Years Randomized Comparison of a Double Induction With Daunorubicin and AraC as Continuous Infusion With a Double Induction With Mitoxantrone and Intermittent Medium High Dose AraC
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mgm2 for 3 days combined with AraC 1gm2 bid on days 1357 compared to a conventional DA 73 protocol 45mgm2 Daunorubicin
Detailed Description:
Randomized comparison of the two protocols
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None